Pfizer gets FDA nod for lung cancer drug Lorbrena
Lorbrena is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to treat patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.